181 related articles for article (PubMed ID: 27044891)
1. P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.
Hashimoto A; Oikawa T; Hashimoto S; Sugino H; Yoshikawa A; Otsuka Y; Handa H; Onodera Y; Nam JM; Oneyama C; Okada M; Fukuda M; Sabe H
J Cell Biol; 2016 Apr; 213(1):81-95. PubMed ID: 27044891
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Hashimoto S; Mikami S; Sugino H; Yoshikawa A; Hashimoto A; Onodera Y; Furukawa S; Handa H; Oikawa T; Okada Y; Oya M; Sabe H
Nat Commun; 2016 Feb; 7():10656. PubMed ID: 26854204
[TBL] [Abstract][Full Text] [Related]
3. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
4. High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue.
Otsuka Y; Sato H; Oikawa T; Onodera Y; Nam JM; Hashimoto A; Fukunaga K; Hatanaka KC; Hatanaka Y; Matsuno Y; Fukuda S; Sabe H
Cell Commun Signal; 2016 Nov; 14(1):28. PubMed ID: 27871329
[TBL] [Abstract][Full Text] [Related]
5. Interplay between Rab35 and Arf6 controls cargo recycling to coordinate cell adhesion and migration.
Allaire PD; Seyed Sadr M; Chaineau M; Seyed Sadr E; Konefal S; Fotouhi M; Maret D; Ritter B; Del Maestro RF; McPherson PS
J Cell Sci; 2013 Feb; 126(Pt 3):722-31. PubMed ID: 23264734
[TBL] [Abstract][Full Text] [Related]
6. Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells.
Handa H; Hashimoto A; Hashimoto S; Sabe H
Small GTPases; 2018 Sep; 9(5):420-426. PubMed ID: 27754741
[TBL] [Abstract][Full Text] [Related]
7. EGF-reduced Wnt5a transcription induces epithelial-mesenchymal transition via Arf6-ERK signaling in gastric cancer cells.
Zhang Y; Du J; Zheng J; Liu J; Xu R; Shen T; Zhu Y; Chang J; Wang H; Zhang Z; Meng F; Wang Y; Chen Y; Xu Y; Gu L
Oncotarget; 2015 Mar; 6(9):7244-61. PubMed ID: 25779663
[TBL] [Abstract][Full Text] [Related]
8. Roles of Arf6 in cancer cell invasion, metastasis and proliferation.
Li R; Peng C; Zhang X; Wu Y; Pan S; Xiao Y
Life Sci; 2017 Aug; 182():80-84. PubMed ID: 28625359
[TBL] [Abstract][Full Text] [Related]
9. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
[TBL] [Abstract][Full Text] [Related]
10. NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer.
Loskutov YV; Kozyulina PY; Kozyreva VK; Ice RJ; Jones BC; Roston TJ; Smolkin MB; Ivanov AV; Wysolmerski RB; Pugacheva EN
Oncogene; 2015 Jul; 34(28):3662-75. PubMed ID: 25241893
[TBL] [Abstract][Full Text] [Related]
11. ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway.
Tague SE; Muralidharan V; D'Souza-Schorey C
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9671-6. PubMed ID: 15210957
[TBL] [Abstract][Full Text] [Related]
12. An ARF6/Rab35 GTPase cascade for endocytic recycling and successful cytokinesis.
Chesneau L; Dambournet D; Machicoane M; Kouranti I; Fukuda M; Goud B; Echard A
Curr Biol; 2012 Jan; 22(2):147-53. PubMed ID: 22226746
[TBL] [Abstract][Full Text] [Related]
13. Arf6 promotes cell proliferation via the PLD-mTORC1 and p38MAPK pathways.
Knizhnik AV; Kovaleva OV; Komelkov AV; Trukhanova LS; Rybko VA; Zborovskaya IB; Tchevkina EM
J Cell Biochem; 2012 Jan; 113(1):360-71. PubMed ID: 21928324
[TBL] [Abstract][Full Text] [Related]
14. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
Morishige M; Hashimoto S; Ogawa E; Toda Y; Kotani H; Hirose M; Wei S; Hashimoto A; Yamada A; Yano H; Mazaki Y; Kodama H; Nio Y; Manabe T; Wada H; Kobayashi H; Sabe H
Nat Cell Biol; 2008 Jan; 10(1):85-92. PubMed ID: 18084281
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 on the Path to Metastasis.
Tang Q; Su Z; Gu W; Rustgi AK
Trends Cancer; 2020 Jan; 6(1):62-73. PubMed ID: 31952783
[TBL] [Abstract][Full Text] [Related]
16. The GTPase ARF6 Controls ROS Production to Mediate Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation.
Bourmoum M; Charles R; Claing A
PLoS One; 2016; 11(1):e0148097. PubMed ID: 26824355
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
18. Suppression of actopaxin impairs hepatocellular carcinoma metastasis through modulation of cell migration and invasion.
Ng L; Tung-Ping Poon R; Yau S; Chow A; Lam C; Li HS; Chung-Cheung Yau T; Law WL; Pang R
Hepatology; 2013 Aug; 58(2):667-79. PubMed ID: 23504997
[TBL] [Abstract][Full Text] [Related]
19. ARF1 and ARF6 are dispensable for Crk-dependent epithelial-mesenchymal-like transitions.
Lamorte L; Park M
Anticancer Res; 2003; 23(3A):2085-92. PubMed ID: 12894582
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
